A recently approved plaque-tracking dye can improve doctors' ability to identify Alzheimer's…"I think it puts the clinician in a bind," says Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center. If a scan is negative, then a doctor can tell a patient that amyloid is not contributing, but if a scan is positive, what should a clinician do? "The FDA nor the company says anything about the meaning of a positive scan," says Petersen. "The data is not out there."

Technology Review  by Susan Young

Tags: alzheimer's disease, Development, Dr. Ronald Petersen, Mayo Clinic Alzheimer's Disease Research Center, Neurology, Technology Review